Menu
Recruiting NCT07367880

The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)

Observational Alzheimer s Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Identification and naming task.
Who it may be relevant to
Registry conditions: Alzheimer s Disease. Basic parameters: 50 years — 95 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this study is to show a significant difference in performance between 2 groups of participants (healthy elderly people vs. people with Alzheimer Disease) in an identification and naming task involving famous monuments.

Interventions

  • Other Identification and naming task
    Task of identification and naming of landmarks and celebrities

Primary outcome measures

  • Difference between the two groups in the identification and naming task involving famous landmarks [Time frame: 1 month]
Secondary outcome measures (1)
  • Development and standardization of a new tool for screening for naming disorders and visual identification of unique entities. [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • Alzheimer's disease:
  • Age ≥ 50 years and older
  • Possible or probable diagnosis of Alzheimer's disease according to the revised criteria of Mac Khann et al., 2011.
  • Score 18≤ MMSE ≤26
  • Controls:
  • Age ≥ 50 years and older
  • MMSE score ≥ 26 For all subjects
  • No objection from the participant

Exclusion criteria

  • Alzheimer's disease:
  • Persons referred to in Articles L1121-5 to L1121-8 of the CSP
  • Controls:
  • Memory complaints
  • Persons referred to in Articles L1121-5 to L1121-8 of the CSP For all subjects
  • Significant neurological or psychiatric history
  • Taking psychotropic medication (neuroleptics)
  • Poor command of the French language, comprehension difficulties
  • Significant hearing or visual impairments (diplopia, nystagmus, scotoma, etc.)
  • Insufficient exposure to the media and/or socio-cultural knowledge (questionnaire) ; Deficit in face recognition (Benton Face Recognition Test)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

France · 1 center
  • CHU Grenoble Alpes — Grenoble

Identifiers

NCT: NCT07367880 · 38RC25.0190_TeDIMO · 2025-A01292-47

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗